Daniel Janney - 14 Sep 2026 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Reporting relationship: Director
Issuer ticker: KRYS
Reported as of: 14 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Sep 2026, 20:01:16 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Krish Krishnan, as attorney-in-fact for Daniel Janney

Key filing fact

Daniel Janney filed Form 4 for Krystal Biotech, Inc. (KRYS) on 16 Sep 2026.

Key facts

This page summarizes Daniel Janney's Form 4 filing for Krystal Biotech, Inc. (KRYS).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 Sep 2026, 20:01.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001198325 Primary reporting owner

JANNEY DANIEL

Relationship: Director
Address: C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH
Signature: /s/ Krish Krishnan, as attorney-in-fact for Daniel Janney
Signature date: 16 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KRYS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +1,187
Change %
Price: $0.000000^*
Shares after: 1,187
Date: 14 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,187
Exercise price: $340.03
Footnotes: F1

KRYS transaction Derivative

Restricted Stock Award

Award

Transaction value
Shares: +471
Change %
Price: $0.000000^*
Shares after: 471
Date: 14 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 471
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

Footnote F2

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

Footnote F3

The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.